No referral incentives
Hospitals and doctors do not pay us for inclusion. The recommendation is not a referral inventory.
Why Us
Choose the side of the patient, not the referral channel.
YourChinaMed is built for families who need an independent China route assessment before a hospital conversation, travel plan, or paid coordination begins.
The difference is structural, not just service language.
Many routes to foreign medical care begin with a hospital, agency, or package. We begin with the patient's decision question and test whether China deserves comparison at all.
Patient-side model
- The patient is the client
- Options are compared before contact
- Recommendations explain fit and tradeoffs
- Paid support starts only when a route is realistic
Referral-channel model
- Hospitals or agencies shape the route
- Provider access can become the recommendation
- Packages are sold before fit is proven
- Uncertainty is hidden behind confident promises
Why families use us before choosing a China route.
Method before access, records before recommendation
We test volume, outcomes, recognition, and suitability from the patient's records before turning a name into a route.
Report-based reasoning
When research is needed, the output explains the evidence, shortlist logic, tradeoffs, practical constraints, and unresolved risks.
Industry-side fluency
Our reviewers understand the operating reality behind China healthcare, from tertiary hospitals to pharma and healthcare-enterprise systems. That is why our reads of access, supply chain, and execution are practical, not theoretical. Meet the team
Permission to say no
If China is not worth comparing for the case, the responsible answer is to stop early.
Our strongest claim is restraint.
We are not trying to prove China is always the answer. We are trying to determine whether one China route is serious enough, specific enough, and practical enough to justify the next step.
Ask if your case fitsMove forward
When the records, timeline, doctor fit, hospital capability, and access path support deeper research.
Wait or verify
When missing records, uncertain staging, or unclear goals make any recommendation premature.
Do not pursue
When the China route adds burden without a credible clinical, timing, access, or cost advantage.
The next step is small.
Send the case. Within 48 hours, we will tell you which answer fits: move forward, wait or verify, or do not pursue. No commitment, no sales follow-up.
Ask if your case fits